Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients
In conclusion, metronomic VNR plus DEX showed favourable activity, and a low toxicity profile, in mCRPC patients. Plasma sB7-H3, VEGF and TSP-1 levels are potential pharmacodynamic markers at the reached low plasma concentrations of vinorelbine metronomically administered.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Dexamethasone | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Prostate Cancer | Study | Toxicology